The latest US FDA approval news from the Pink Sheet’s US FDA Performance Tracker

Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.

Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.

Sandoz will be able to launch a generic of Adamas’ amantadine-based Gocovri brand in the US from March 2030. But a patent-litigation settlement permits an earlier entry if sales of the dyskinesia brand decline.